UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13A-17 OR 15D-17 THEREUNDER
The Liposome Company, Inc.
(Exact name of issuer as specified in charter)
One Research Way, Princeton Forrestal Center, Princeton, NJ 08540
(Address of principal Executive offices)
Issuer's telephone number, including area code (609) 452-7060
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1. Title of Security
Common Stock, par value $.01 per share
2. Number of shares
outstanding before the change 30,295,690
3. Number of shares
outstanding after the change 32,958,774
4. Effective date of
change March 25, 1996 (effective date of redemption and sale)
March 28, 1996 (closing date)
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.) Conversion of
Preferred Stock and Distribution
Give brief description of transaction Depositary Shares representing Series
A Preferred Stock called for redemption were
converted into 2,645,848 shares Common Stock, and 17,236 shares of Common
Stock were sold pursuant to Standby Purchase Agreement registered on
Registration No. 333-1169.
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
2. Name after change
3. Effective date of
charter amendment changing name
4. Date of shareholder
approval of change, if required
Date April 2, 1996
(Officer's signature & title)
Vice President, General Counsel and Secretary
